Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) braziliensis
Pathogens · 2024
DOI: 10.3390/pathogens13040301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Carvel Suprien und 3 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University of Bahia, Salvador 40026-010, Bahia, Brazil. Hauptthemen laut MEDLINE: Leishmaniasis, Cutaneous, Leishmania braziliensis, Granulocyte Colony-Stimulating Factor, Antiprotozoal Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Nacional de Ciência e Tecnologia de Doenças Tropicais, National Institutes of Science and Technology in Tropical Diseases (INCT-DT), Ministry of Science and Technology (MCTI/CNPq/CAPES/FAPS).
Abstract (Originalsprache)
Cutaneous leishmaniasis (CL), caused by Leishmania braziliensis, in recent decades has shown decreasing cure rates after treatment with meglumine antimoniate (MA). Granulocyte colony-stimulating factor (G-CSF) is a cytokine associated with epithelialization and healing processes.
Methods
This study compares the effectiveness of G-CSF associated with MA in the treatment of CL. A total of 32 patients aged between 18 and 50 years with CL confirmed for L. braziliensis were included in this study. G-CSF or placebo (0.9% saline) was applied by intralesional infiltration at four equidistant points on the edges of the largest ulcer on days 0 and 15 of treatment associated with intravenous MA.
Results
Males predominated in the G-CSF group (59%), while females predominated in the control group (53%). Injuries to the lower limbs predominated in both study groups. The cure rate in the G-CSF group was 65% and in the control group it was 47%, 90 days after initiation of therapy.
Conclusions
Our data indicate that the association of G-CSF with MA is not superior to MA monotherapy. Although not significant, the potential benefit of this combination deserves further investigation. The use of higher doses or other routes of application of G-CSF in a greater number of patients should contribute to a definitive response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University of Bahia, Salvador 40026-010, Bahia, Brazil.
- National Institutes of Science and Technology in Tropical Diseases, Ministry of Science and Technology, Salvador, Bahia, Brazil.
- Medicine School, Federal University of Recôncavo Bahia, Santo Antônio de Jesus 44380-000, Bahia, Brazil.
- Immunology Service of the Professor Edgard Santos University Hospital, Federal University of Bahia, Salvador 40110-060, Bahia, Brazil.
- Gonçalo Moniz Institute, Fiocruz, Salvador 40296-710, Bahia, Brazil.
ORCID-Profile: Carvel Suprien, Paulo R L Machado
Förderung
- Instituto Nacional de Ciência e Tecnologia de Doenças Tropicais
- National Institutes of Science and Technology in Tropical Diseases (INCT-DT)
- Ministry of Science and Technology (MCTI/CNPq/CAPES/FAPS)
Zitieren
APA
Suprien, C., Guimarães, L. H., de Carvalho, L. P., & Machado, P. R. L. (2024). Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) braziliensis. Pathogens. https://doi.org/10.3390/pathogens13040301
Vancouver
Suprien C, Guimarães LH, de Carvalho LP, Machado PRL. Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) braziliensis. Pathogens. 2024. doi:10.3390/pathogens13040301
BibTeX
@article{Suprien2024,
author = {Suprien, Carvel and Guimarães, Luiz H and de Carvalho, Lucas P and Machado, Paulo R L},
title = {Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) braziliensis},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13040301}
}
EUVIMED